Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
Obesity and Type 2 diabetes are creating a silent epidemic, Non-alcoholic fatty liver disease, which is a chronic liver disease associated with insulin resistance, impaired glucose intolerance, and hepatic fat accumulation.
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT00994682
- Testing
- Pioglitazone study drug, Pioglitazone Open Label
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of Florida
NAFLD, Non-alcoholic Fatty Liver Disease
Manual Therapy in Metabolic Liver Disease
Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver.
- Trial name
- OSTEO-EHMet (NCT06338618)
- Testing
- liver treatment protocol
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Seville
NAFLD
Treatment of NAFLD With Two Different Diets
The impact of popular diets on liver-related health is unclear. In this randomized, controlled trial, patients with NAFLD will be randomized to one of two popular diets or a placebo diet.
- Trial name
- TREND (NCT03118310)
- Testing
- 5:2 diet, LCHF
- Where
- Sweden
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Diseases, Liver Transplant; Complications
Prognostic Factors After Liver Transplantation
The study retrospectively reviewed the medical records of patients who received adult liver transplantation in Changhua Christian hospital from 2002 to 2019.
- Trial name
- NCT05018741
- Testing
- liver transplantation
- Volunteers
- 600 people
- Sponsor
- Changhua Christian Hospital
Obesity, Diabetes
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance
The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects
- Conditions
- Obesity, Diabetes, Insulin Resistance, Fatty Liver
- Trial name
- HEPFAT (NCT01038102)
- Testing
- PUFA Diet, SFA diet
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Nonalcoholic Fatty Liver Disease
Role of Exenatide in NASH-a Pilot Study
We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.
- Trial name
- NAFLD (NCT00650546)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Non-alcoholic Steatohepatitis, Hepatic Impairment
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
- Trial name
- NCT06052566
- Testing
- Efinopegdutide
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alcoholic Hepatitis
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Inflammatory responses in response to alcohol have been identified as contributing to the development of alcoholic hepatitis. The inflammatory response including that to LippoPolySaccharide is known to lead to progression of…
- Trial name
- NCT04088370
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
HIV Infections, Fatty Liver Disease
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression…
- Trial name
- MAFALDA-R (NCT05898841)
- Testing
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion SEIMC-GESIDA
NASH - Nonalcoholic Steatohepatitis
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed…
- Trial name
- NCT03551522
- Testing
- Seladelpar
- Where
- 14 sites in United States
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Alcoholic Liver Disease
Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)
The current goal in the treatment of Alcoholic Liver Disease (ALD) is to manage ALD-associated complications as there are no disease-specific therapies.
- Trial name
- NCT03113929
- Testing
- MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03213145
- Testing
- intraconazole, Rifampin, EDP 305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Non Alcoholic Fatty Liver Disease
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.
- Trial name
- NCT01999101
- Testing
- Px-104
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Phenex Pharmaceuticals AG
Alcoholic Liver Disease, Liver Cirrhosis, Alcoholic
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
Investigators wishes to influence the gut microbiota in patients with alcoholic liver disease in a randomized controlled clinical trial.
- Conditions
- Alcoholic Liver Disease, Liver Cirrhosis, Alcoholic, Probiotics, Liver Fibrosis
- Trial name
- SYN-ALD (NCT03863730)
- Testing
- Profermin Plus, FSMP, probiotics, Fresubin, dietary supplement
- Where
- 2 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Odense University Hospital
Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Conditions
- Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, Insulin Resistance
- Trial name
- GC-NASH (NCT01553500)
- Testing
- glucomannan, lifestyle intervention
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
NAFLD, Hiv
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and will likely become the predominant cause of chronic liver disease in HIV-infected individuals.
- Trial name
- NCT03913351
- Testing
- Lifestyle modification
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
- Trial name
- Harmony (NCT04767529)
- Testing
- Efruxifermin
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 128 people
- Sponsor
- Akero Therapeutics, Inc
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
- Trial name
- PROXYMO-ADV (NCT05364931)
- Testing
- Cotadutide
- Where
- 115 sites in United States, Argentina and 18 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.